It's likely there was an improvement in mortality if it passed the interim readout at 45%, just not one that would pass the trial at the given powering.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-284
-
- There are more pages in this discussion • 792 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.000(0.00%) |
Mkt cap ! $1.609B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $2.126M | 1.496M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 14125 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.44 | 2007 | 4 |
View Market Depth
| Last trade - 14.14pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |